Vical (VICL) Announces that In Vivo Testing of Vaxfactin Shows Increase in Antibody and T-Cell Responses
Tweet Send to a Friend
Vical Incorporated (NASDAQ: VICL) announced today that systematic in vivo testing of the company's Vaxfectin adjuvant shows that it increased ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
